MX2014012977A - Anticuerpos anti-cd22. - Google Patents

Anticuerpos anti-cd22.

Info

Publication number
MX2014012977A
MX2014012977A MX2014012977A MX2014012977A MX2014012977A MX 2014012977 A MX2014012977 A MX 2014012977A MX 2014012977 A MX2014012977 A MX 2014012977A MX 2014012977 A MX2014012977 A MX 2014012977A MX 2014012977 A MX2014012977 A MX 2014012977A
Authority
MX
Mexico
Prior art keywords
antibodies
methods
encode
vectors
antibody
Prior art date
Application number
MX2014012977A
Other languages
English (en)
Other versions
MX361533B (es
Inventor
Jay Short
Hwai Wen Chang
Gerhard Frey
William Boyle
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Publication of MX2014012977A publication Critical patent/MX2014012977A/es
Publication of MX361533B publication Critical patent/MX361533B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se describen anticuerpos anti-CD22, que incluyen ácidos nucleicos aislados que codifican para por lo menos uno de dicho anticuerpo anti-CD22, vectores, células hospederas, animales o plantas transgénicos, métodos para producir y usar los mismos, que incluyen composiciones terapéuticas, métodos y dispositivos.
MX2014012977A 2012-04-26 2013-04-26 Anticuerpos anti-cd22. MX361533B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261638834P 2012-04-26 2012-04-26
PCT/US2013/038370 WO2013163519A1 (en) 2012-04-26 2013-04-26 Anti-cd22 antibodies

Publications (2)

Publication Number Publication Date
MX2014012977A true MX2014012977A (es) 2015-02-05
MX361533B MX361533B (es) 2018-12-07

Family

ID=49483918

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012977A MX361533B (es) 2012-04-26 2013-04-26 Anticuerpos anti-cd22.

Country Status (12)

Country Link
US (2) US9856323B2 (es)
EP (1) EP2841459A4 (es)
JP (1) JP2015516984A (es)
KR (1) KR20150008080A (es)
CN (1) CN104428316A (es)
AU (2) AU2013251482B2 (es)
BR (1) BR112014026744A8 (es)
CA (1) CA2871764A1 (es)
HK (1) HK1207653A1 (es)
MX (1) MX361533B (es)
RU (1) RU2014147452A (es)
WO (1) WO2013163519A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014057118A1 (en) * 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
JOP20200157A1 (ar) 2017-12-22 2022-10-30 Teneobio Inc أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
UY38748A (es) 2019-06-14 2021-01-29 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
WO2021083467A1 (en) * 2019-10-28 2021-05-06 Y-Mabs Therapeutics, Inc. Administration of cd22, cd33 and/or tim-3 antibodies using ommaya reservoirs for the treatment of cns cancer or neurodegenerative diseases
WO2021197483A1 (zh) * 2020-04-02 2021-10-07 南京驯鹿医疗技术有限公司 全人源抗人cd22的嵌合抗原受体及其应用
CN113527507A (zh) 2020-04-16 2021-10-22 上海赛比曼生物科技有限公司 靶向cd22的嵌合抗原受体及其制法和应用
US20240092903A1 (en) * 2020-06-12 2024-03-21 Ichnos Sciences SA Antibody formulation diluent
US20230365709A1 (en) 2020-10-08 2023-11-16 Affimed Gmbh Trispecific binders
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
CA3233696A1 (en) 2021-11-03 2023-05-11 Joachim Koch Bispecific cd16a binders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2251723T3 (es) * 1994-08-12 2006-05-01 Immunomedics, Inc. Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia.
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
EP2540741A1 (en) * 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
RS54163B1 (en) 2006-05-30 2015-12-31 Genentech Inc. ANTI-CD22 ANTIBODIES, THEIR IMMUNCONJUGATES AND THEIR USE
KR20150067395A (ko) 2006-12-01 2015-06-17 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
WO2014057118A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates

Also Published As

Publication number Publication date
BR112014026744A2 (pt) 2017-07-11
EP2841459A1 (en) 2015-03-04
CA2871764A1 (en) 2013-10-31
AU2013251482A1 (en) 2014-10-30
BR112014026744A8 (pt) 2018-01-16
KR20150008080A (ko) 2015-01-21
CN104428316A (zh) 2015-03-18
MX361533B (es) 2018-12-07
AU2017268687A1 (en) 2017-12-21
HK1207653A1 (en) 2016-02-05
JP2015516984A (ja) 2015-06-18
US9856323B2 (en) 2018-01-02
EP2841459A4 (en) 2016-04-13
US20150086562A1 (en) 2015-03-26
RU2014147452A (ru) 2016-06-20
US20180086843A1 (en) 2018-03-29
WO2013163519A1 (en) 2013-10-31
AU2013251482B2 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
MX361533B (es) Anticuerpos anti-cd22.
PH12016501644A1 (en) Binding proteins and methods of use thereof
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
MX2017008819A (es) Anticuerpos anti-cd47 y usos de los mismos.
PH12015502293A1 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
MX2017006802A (es) Animales no humanos que expresan el complejo cd3 humanizado.
BR112017024123A2 (pt) construtos de expressão e métodos de manipulação por engenharia genética de levedura metilotrófica
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
EP3604535A3 (en) Methods and compositions for weed control
MX369653B (es) Formulaciones de anticuerpos y proteinas.
GB2547587A (en) Transgenic mice
MX2010004179A (es) Anticuerpos anti-amiloide, composiciones, metodos y usos.
TW201613893A (en) Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
PH12018501317A1 (en) Compositions and methods for efficient targeting of transgenes
EP3320773A4 (en) NON-HUMAN ANIMAL HAVING A CD3 HUMAN GENE SUBSTITUTED WITH ENDOGENOUS CD3 GENE
MX2021005373A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
MX2016013241A (es) Animales no humanos que tienen receptores fc gamma humanizados.
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
JOP20210010A1 (ar) بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
MX2017000527A (es) Formulaciones de anticuerpos cristalinos.
MX2021006003A (es) Formulaciones de anticuerpos cristalinos.
MX366208B (es) Transformación de la lenteja de agua y sus usos.
MX2015016610A (es) Medios y metodos para producir rendimiento en plantas.

Legal Events

Date Code Title Description
FG Grant or registration